Überlegungen zur arzneimitteldosierung bei patienten mit akuter und chronischer nierenerkrankung - Eine klinische aktualisierung von Kidney Disease

Improving Global Outcomes (KDIGO)

Translated title of the contribution: Drug dosing consideration in patients with acute and chronic kidney disease - A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

G. R. Matzke, G. R. Aronoff, A. J. Atkinson, W. M. Bennett, Brian Decker, K. U. Eckardt, T. Golper, D. W. Grabe, B. Kasiske, F. Keller, J. T. Kielstein, R. Mehta, B. A. Mueller, D. A. Pasko, F. Schaefer, D. A. Sica, L. A. Inker, J. G. Umans, P. Murray

Research output: Contribution to journalArticle

Abstract

Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patient's kidney function in both acute and chronic kidney disease and determine the influence of renal replacement therapies on drug disposition. Kidney Disease: Improving Global Outcomes (KDIGO) held a conference to investigate these issues and propose recommendations for practitioners, researchers, and those involved in the drug development and regulatory arenas. The conference attendees discussed themajor challenges facing drug dosage adjustment for patients with kidney disease. In particular, although glomerular filtration rate is the metric used to guide dose adjustment, kidney disease does affect nonrenal clearances, and this is not adequately considered in most pharmacokinetic studies. There are also inadequate studies in patients receiving all forms of renal replacement therapy and in the pediatric population. The conference generated 37 recommendations for clinical practice, 32 recommendations for future research directions, and 24 recommendations for regulatory agencies (US Food and Drug Administration and European Medicines Agency) to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. The KDIGO Conference highlighted the gaps and focused on crafting paths to the future that will stimulate research and improve the global outcomes of patients with acute and chronic kidney disease.

Original languageGerman
Pages (from-to)45-61
Number of pages17
JournalNieren- und Hochdruckkrankheiten
Volume41
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Kidney Diseases
Chronic Renal Insufficiency
Pharmaceutical Preparations
Renal Replacement Therapy
Pharmacokinetics
United States Food and Drug Administration
Glomerular Filtration Rate
Research Personnel
Pediatrics
Kidney
Research
Population

Keywords

  • Acute kidney injury (AKI)
  • Chronic kidney disease (CKD)
  • Continuous renal replacement therapy
  • Drug dosing
  • Hemodialysis
  • Pharmacokinetics

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Überlegungen zur arzneimitteldosierung bei patienten mit akuter und chronischer nierenerkrankung - Eine klinische aktualisierung von Kidney Disease : Improving Global Outcomes (KDIGO). / Matzke, G. R.; Aronoff, G. R.; Atkinson, A. J.; Bennett, W. M.; Decker, Brian; Eckardt, K. U.; Golper, T.; Grabe, D. W.; Kasiske, B.; Keller, F.; Kielstein, J. T.; Mehta, R.; Mueller, B. A.; Pasko, D. A.; Schaefer, F.; Sica, D. A.; Inker, L. A.; Umans, J. G.; Murray, P.

In: Nieren- und Hochdruckkrankheiten, Vol. 41, No. 2, 02.2012, p. 45-61.

Research output: Contribution to journalArticle

Matzke, GR, Aronoff, GR, Atkinson, AJ, Bennett, WM, Decker, B, Eckardt, KU, Golper, T, Grabe, DW, Kasiske, B, Keller, F, Kielstein, JT, Mehta, R, Mueller, BA, Pasko, DA, Schaefer, F, Sica, DA, Inker, LA, Umans, JG & Murray, P 2012, 'Überlegungen zur arzneimitteldosierung bei patienten mit akuter und chronischer nierenerkrankung - Eine klinische aktualisierung von Kidney Disease: Improving Global Outcomes (KDIGO)', Nieren- und Hochdruckkrankheiten, vol. 41, no. 2, pp. 45-61. https://doi.org/10.5414/NHX01415
Matzke, G. R. ; Aronoff, G. R. ; Atkinson, A. J. ; Bennett, W. M. ; Decker, Brian ; Eckardt, K. U. ; Golper, T. ; Grabe, D. W. ; Kasiske, B. ; Keller, F. ; Kielstein, J. T. ; Mehta, R. ; Mueller, B. A. ; Pasko, D. A. ; Schaefer, F. ; Sica, D. A. ; Inker, L. A. ; Umans, J. G. ; Murray, P. / Überlegungen zur arzneimitteldosierung bei patienten mit akuter und chronischer nierenerkrankung - Eine klinische aktualisierung von Kidney Disease : Improving Global Outcomes (KDIGO). In: Nieren- und Hochdruckkrankheiten. 2012 ; Vol. 41, No. 2. pp. 45-61.
@article{5308177a42e54aa4a65a8c36a703bd5a,
title = "{\"U}berlegungen zur arzneimitteldosierung bei patienten mit akuter und chronischer nierenerkrankung - Eine klinische aktualisierung von Kidney Disease: Improving Global Outcomes (KDIGO)",
abstract = "Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patient's kidney function in both acute and chronic kidney disease and determine the influence of renal replacement therapies on drug disposition. Kidney Disease: Improving Global Outcomes (KDIGO) held a conference to investigate these issues and propose recommendations for practitioners, researchers, and those involved in the drug development and regulatory arenas. The conference attendees discussed themajor challenges facing drug dosage adjustment for patients with kidney disease. In particular, although glomerular filtration rate is the metric used to guide dose adjustment, kidney disease does affect nonrenal clearances, and this is not adequately considered in most pharmacokinetic studies. There are also inadequate studies in patients receiving all forms of renal replacement therapy and in the pediatric population. The conference generated 37 recommendations for clinical practice, 32 recommendations for future research directions, and 24 recommendations for regulatory agencies (US Food and Drug Administration and European Medicines Agency) to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. The KDIGO Conference highlighted the gaps and focused on crafting paths to the future that will stimulate research and improve the global outcomes of patients with acute and chronic kidney disease.",
keywords = "Acute kidney injury (AKI), Chronic kidney disease (CKD), Continuous renal replacement therapy, Drug dosing, Hemodialysis, Pharmacokinetics",
author = "Matzke, {G. R.} and Aronoff, {G. R.} and Atkinson, {A. J.} and Bennett, {W. M.} and Brian Decker and Eckardt, {K. U.} and T. Golper and Grabe, {D. W.} and B. Kasiske and F. Keller and Kielstein, {J. T.} and R. Mehta and Mueller, {B. A.} and Pasko, {D. A.} and F. Schaefer and Sica, {D. A.} and Inker, {L. A.} and Umans, {J. G.} and P. Murray",
year = "2012",
month = "2",
doi = "10.5414/NHX01415",
language = "German",
volume = "41",
pages = "45--61",
journal = "Nieren- und Hochdruckkrankheiten",
issn = "0300-5224",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

TY - JOUR

T1 - Überlegungen zur arzneimitteldosierung bei patienten mit akuter und chronischer nierenerkrankung - Eine klinische aktualisierung von Kidney Disease

T2 - Improving Global Outcomes (KDIGO)

AU - Matzke, G. R.

AU - Aronoff, G. R.

AU - Atkinson, A. J.

AU - Bennett, W. M.

AU - Decker, Brian

AU - Eckardt, K. U.

AU - Golper, T.

AU - Grabe, D. W.

AU - Kasiske, B.

AU - Keller, F.

AU - Kielstein, J. T.

AU - Mehta, R.

AU - Mueller, B. A.

AU - Pasko, D. A.

AU - Schaefer, F.

AU - Sica, D. A.

AU - Inker, L. A.

AU - Umans, J. G.

AU - Murray, P.

PY - 2012/2

Y1 - 2012/2

N2 - Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patient's kidney function in both acute and chronic kidney disease and determine the influence of renal replacement therapies on drug disposition. Kidney Disease: Improving Global Outcomes (KDIGO) held a conference to investigate these issues and propose recommendations for practitioners, researchers, and those involved in the drug development and regulatory arenas. The conference attendees discussed themajor challenges facing drug dosage adjustment for patients with kidney disease. In particular, although glomerular filtration rate is the metric used to guide dose adjustment, kidney disease does affect nonrenal clearances, and this is not adequately considered in most pharmacokinetic studies. There are also inadequate studies in patients receiving all forms of renal replacement therapy and in the pediatric population. The conference generated 37 recommendations for clinical practice, 32 recommendations for future research directions, and 24 recommendations for regulatory agencies (US Food and Drug Administration and European Medicines Agency) to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. The KDIGO Conference highlighted the gaps and focused on crafting paths to the future that will stimulate research and improve the global outcomes of patients with acute and chronic kidney disease.

AB - Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted standard of practice. The challenge is how to accurately estimate a patient's kidney function in both acute and chronic kidney disease and determine the influence of renal replacement therapies on drug disposition. Kidney Disease: Improving Global Outcomes (KDIGO) held a conference to investigate these issues and propose recommendations for practitioners, researchers, and those involved in the drug development and regulatory arenas. The conference attendees discussed themajor challenges facing drug dosage adjustment for patients with kidney disease. In particular, although glomerular filtration rate is the metric used to guide dose adjustment, kidney disease does affect nonrenal clearances, and this is not adequately considered in most pharmacokinetic studies. There are also inadequate studies in patients receiving all forms of renal replacement therapy and in the pediatric population. The conference generated 37 recommendations for clinical practice, 32 recommendations for future research directions, and 24 recommendations for regulatory agencies (US Food and Drug Administration and European Medicines Agency) to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. The KDIGO Conference highlighted the gaps and focused on crafting paths to the future that will stimulate research and improve the global outcomes of patients with acute and chronic kidney disease.

KW - Acute kidney injury (AKI)

KW - Chronic kidney disease (CKD)

KW - Continuous renal replacement therapy

KW - Drug dosing

KW - Hemodialysis

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84858025748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858025748&partnerID=8YFLogxK

U2 - 10.5414/NHX01415

DO - 10.5414/NHX01415

M3 - Article

VL - 41

SP - 45

EP - 61

JO - Nieren- und Hochdruckkrankheiten

JF - Nieren- und Hochdruckkrankheiten

SN - 0300-5224

IS - 2

ER -